SCHEMBL874895

SCHEMBL874895

CCCCCCCCCCCCC1CCCCNC1=O

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 10/20 0.52
CCR1 P32246 1/20 0.48
CCR5 P51681 1/20 0.48
CXCR4 P61073 1/20 0.48
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
CYP19A1 P11511 4/20 0.42
NOD1 Q9Y239 1/20 0.41
HTT P42858 1/20 0.40
CYP1A2 P05177 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28510248 1.00 CCR2 (0.52) CCR2CCR1CCR5CXCR4PSEN1
SCHEMBL5871975 1.00 CCR2 (0.52) CCR2CCR1CCR5CXCR4PSEN1
SCHEMBL229898 1.00 CCR2 (0.52) CCR2CCR1CCR5CXCR4PSEN1
SCHEMBL15253305 1.00 CCR2 (0.52) CCR2CCR1CCR5CXCR4PSEN1
SCHEMBL9003899 1.00 CCR2 (0.52) CCR2CCR1CCR5CXCR4PSEN1
SCHEMBL181231 0.98 CCR2 (0.51) CCR2CCR1CCR5CXCR4PSEN1
SCHEMBL9978692 0.95 CCR2 (0.47) CCR2CCR1CCR5CXCR4PSEN1
SCHEMBL7622441 0.95 CCR2 (0.47) CCR2CCR1CCR5CXCR4PSEN1
SCHEMBL1401505 0.93 CCR2 (0.46) CCR2CCR1CCR5CXCR4PSEN1
SCHEMBL1706310 0.93 CCR2 (0.48) CCR2CCR1CCR5CXCR4PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240390279-A1 MICELLAR SOLUTION COMPRISING DICLOFENAC HALEON CH SARL (CH) 2024-11-28 US claimed
EP-4362910-A1 MICELLAR SOLUTION COMPRISING DICLOFENAC Haleon CH SARL (CH) 2024-05-08 EP claimed
CN-116209428-A Treatment of emesis and nausea with minimal doses of olanzapine 斯塔顿治疗公司 2023-06-02 CN claimed
WO-2023275003-A1 MICELLAR SOLUTION COMPRISING DICLOFENAC GSK CONSUMER HEALTHCARE SARL (CH) 2023-01-05 WO claimed
EP-4112041-A1 MICELLAR SOLUTION COMPRISING DICLOFENAC GSK Consumer Healthcare SARL (CH) 2023-01-04 EP claimed
CN-114901287-A Treatment of emesis and nausea with minimal dose of olanzapine 斯塔顿治疗公司 2022-08-12 CN claimed
EP-2531229-B1 MEDICINE PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE HEMOTEQ AG (DE) 2014-12-31 EP claimed
CN-102905735-B Medical product with particle-free coating releasing active substance HEMOTEQ AG 2014-12-03 CN claimed
US-20130245058-A1 MEDICAL PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE HEMOTEQ AG (DE) 2013-09-19 US claimed
CN-102905735-A Medical product with particle-free coating releasing active substance HEMOTEQ AG 2013-01-30 CN claimed
WO-2011147408-A2 MEDICAL PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE HEMOTEQ AG (DE) 2011-12-01 WO claimed
EP-1024691-A4 SOLUBLE POLYMER BASED MATRIX FOR CHEMICALLY ACTIVE WATER INSOLUBLE COMPONENTS ISP INVESTMENTS INC (US) 2004-08-18 EP claimed
CN-1084146-C Emulsifiable composition for disinsectization RHONE POULENC AGROCHIMIE (FR) 2002-05-08 CN claimed
EP-1024691-A1 SOLUBLE POLYMER BASED MATRIX FOR CHEMICALLY ACTIVE WATER INSOLUBLE COMPONENTS ISP INVESTMENTS INC. (US) 2000-08-09 EP claimed
WO-1998033378-A1 SOLUBLE POLYMER BASED MATRIX FOR CHEMICALLY ACTIVE WATER INSOLUBLE COMPONENTS ISP INVESTMENTS INC. (US) 1998-08-06 WO claimed
US-5776856-A Soluble polymer based matrix for chemically active water insoluble components ISP INVESTMENTS INC. (US) 1998-07-07 US claimed
CN-1166773-A Emulsifiable composition for disinsectization RHONE POULENC AGROCHIMIE (FR) 1997-12-03 CN claimed
EP-0794702-A2 EMULSIFIABLE COMPOSITION FOR THE CONTROL OF INSECTS RHONE-POULENC AGROCHIMIE (FR) 1997-09-17 EP claimed
WO-1996016544-A2 EMULSIFIABLE COMPOSITION FOR THE CONTROL OF INSECTS RHONE-POULENC AGROCHIMIE (FR) 1996-06-06 WO claimed
EP-0552879-A1 Improved iontophoretic administration of drugs MACROCHEM CORPORATION (US) 1993-07-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245058-A1 MEDICAL PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE CD44, VEGFA, CD63 CCR2 1208/4885CCR1 581/4885CCR5 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.